Dendreon Files For Bankruptcy, Stock Tanks
Article By:
Terry Chrisomalis
Read
Monday, November 10, 2014 6:47 PM EDT
Dendreon files for Chapter 11 bankruptcy after disappointing sales for Provenge
U.S. Stocks Switched Between Small Gains And Losses
Article By:
BioMedReports
Read
Friday, November 7, 2014 4:36 PM EDT
With the main benchmarks hovering near record levels in the wake of a solid jobs report, a key payrolls data showed the economy added 214,000 jobs in October, while the unemployment rate ticked down to 5.8% — a broadly positive reading.
Shares Of Intercept Pharmaceuticals Tumble 20% After NASH Data Posted Shows Safety Concerns
Article By:
Terry Chrisomalis
Read
Friday, November 7, 2014 11:31 AM EDT
Two major problems are reported that mean a significant setback for Intercept's lead OCA drug.
In this article: ICPT
Aeterna Zentaris Receives CRL From FDA For Adult Growth Hormone Deficiency Test
Article By:
Terry Chrisomalis
Read
Thursday, November 6, 2014 7:02 PM EDT
FDA sends AEZS back to the drawing board with Macrilen.
In this article: AEZS
ASH 2014 Abstracts Are About To Hit: Here Are Some Of The Names To Follow
Article By:
PropThink
Read
Thursday, November 6, 2014 8:30 AM EDT
One of the biggest events in healthcare annually, the American Society of Hematology’s annual meeting (56th!) begins on December 6, but abstracts from the conference will be released this morning. Here's a primer on the stocks to watch.
ALNY Completes Phase 2 Enrollment; FDA Grants Orphan Drug Designation To MACK
Article By:
BioMedReports
Read
Thursday, November 6, 2014 4:11 AM EDT
Alnylam Pharmaceuticals announced it has completed enrollment in its Phase 2 clinical trial with revusiran.Merrimack Pharmaceuticals announced the U.S. FDA has granted orphan drug designation for the treatment of pancreatic cancer.
AZN And PCYC Enter Clinical Trial Collaboration To Evaluate IMBRUVICA
Article By:
BioMedReports
Read
Wednesday, November 5, 2014 3:14 AM EDT
AstraZeneca and Pharmacyclics will collaborate on a non-exclusive basis and multiple studies may be considered and conducted. The studies will be led by AstraZeneca.
MannKind Falls On Missing Q3 Estimates Yet Cuts Loss Y/Y
Article By:
Zacks Investment Research
Read
Tuesday, November 4, 2014 4:24 PM EDT
Shares of MannKind Corporation were down 1.5% after the company reported a loss of 9 cents per share in the third quarter of 2014, narrower than the year-ago loss of 17 cents per share.
In this article: MNKD
Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows
Article By:
Zacks Investment Research
Read
Tuesday, November 4, 2014 11:41 AM EDT
Arena Pharma recorded third-quarter revenues of $8.2 million, below the Zacks Consensus Estimate of $10 million.
In this article: ARNA
Geron Shares Surge 25% After The Removal Of A Clinical Hold By The FDA
Article By:
Terry Chrisomalis
Read
Tuesday, November 4, 2014 10:42 AM EDT
Imetelstat, a key blood cancer drug, is taken off FDA hold and can proceed to trial.
In this article: GERN
Why The World Should Be Thanking Japan
Article By:
Bill Bonner
Read
Monday, November 3, 2014 6:57 PM EDT
Japan is going to show us that you don’t have to be a Third World kleptocracy — such as Zimbabwe — to undertake extraordinary and disastrous policies.
MannKind Corporation Reports 2014 Third Quarter Financial Results
Article By:
TalkMarkets DailyTalk
Read
Monday, November 3, 2014 6:01 PM EDT
For the third quarter of 2014, total operating expenses were $38.3 million, compared to $44.8 million for the third quarter of 2013, a decrease of $6.5 million. (Earnings release)
In this article: MNKD
Pause In Rally Maintains Friday's Gains
Article By:
Declan Fallon
Read
Monday, November 3, 2014 5:35 PM EDT
Friday's breakouts were small, and vulnerable to selling and 'bull traps', but today's action stayed close to Friday's highs, keeping bulls happy.